FMP
Dyne Therapeutics, Inc.
DYN
NASDAQ
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
15.29 USD
-0.58 (-3.79%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. John G. Cox M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.dyne-tx.comexchange
NASDAQ
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
CIK
0001818794
ISIN
US26818M1080
CUSIP
26818M108
Address
1560 Trapelo Road
Phone
781 786 8230
Country
US
Employee
173
IPO Date
Sep 17, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
DYN Financial Summary
CIK
0001818794
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
26818M108
ISIN
US26818M1080
Country
US
Price
15.29
Beta
1.09
Volume Avg.
1.1M
Market Cap
1.56B
Shares
-
52-Week
14.792-47.45
DCF
1.58
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.27
P/B
-
Website
https://www.dyne-tx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DYN News
It looks like there's no news available.
